

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1611

KNEISSEL ET AL.

APPLICATION NO: 10/563,707

Examiner: Joseph S. Kudla

FILED: JANUARY 6, 2006

FOR: USE OF RAPAMYCIN AND RAPAMYCIN DERIVATIVES FOR THE
TREATMENT OF BONE LOSS

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL RESPONSE TO RESTRICTION REQUIREMENT


Sir:

Further the Applicant's response to the Restriction/election of species mailed on 3/4/08,
Applicants elect osteoporosis as a disease.

Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-2614



Gregory C. Houghton
Attorney for Applicants
Reg. No. 47,666

Date: June 13, 2008